J A Rauh-Hain Selected Research

Sunitinib (Sutent)

9/2008

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J A Rauh-Hain Research Topics

Disease

3	Neoplasms (Cancer) 01/2017 - 01/2012
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017
1	Vulvar Neoplasms (Vulvar Cancer) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 08/2013
1	Ovarian Epithelial Carcinoma 08/2013
1	Endometrial Neoplasms (Endometrial Cancer) 01/2012
1	Carcinoma (Carcinomatosis) 01/2010
1	Endometrioid Carcinoma 01/2010
1	Neoplasm Metastasis (Metastasis) 09/2008
1	Clear Cell Adenocarcinoma 09/2008

Drug/Important Bio-Agent (IBA)

1	Small Interfering RNA (siRNA)IBA 08/2013
1	Histone Deacetylase InhibitorsIBA 08/2013
1	Co-Repressor ProteinsIBA 08/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2012
1	Cisplatin (Platino)FDA LinkGeneric 01/2012
1	Etoposide (VP 16)FDA LinkGeneric 01/2012
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2012
1	Carboplatin (JM8)FDA LinkGeneric 01/2012
1	Sunitinib (Sutent)FDA Link 09/2008

Therapy/Procedure

1	Vulvectomy 01/2017
1	Patient Readmission 01/2017
1	Adjuvant Chemotherapy 01/2012
1	Therapeutics 01/2010
1	Drug Therapy (Chemotherapy) 09/2008